Oncolytics Biotech Inc T.ONC

ONCY pelareorep as a potential bispecific or ADC payload.

[Noteable]

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7175114/

[Noteable]

ONCY has demonstrated that pelareorep is capable of remodeling the TME. And we also found that poor infiltration of immune effector cells and complex immunosuppressive TME in solid tumors requires combination therapies consisting of multispecific antibodies with other immunomodulatory agents, for example, immune checkpoint blockers, personalized neoantigen vaccines, and oncolytic

[Noteable]

Galon, J. & Bruni, D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat. Rev. Drug Discov. 18, 197–218 (2019).

[Noteable]

From failure to success A major advancement in the understanding of the concept of ADCs followed research studies arming antibodies with toxic molecules, such as diphtheria toxin (first proposed in 1970 by Frederick L. Moolten and Sidney R. Cooperband) and radioisotopes. These studies, in which antibodies were conjugated to radioisotopes, initially failed in early

[Noteable]

Despite their antibody-directed homing, ADcs come with their share of toxicities obligating appropriate patient selection and vigilant monitoring while on treatment. As more ADCs are included in the treatment armamentarium, mechanisms of resistance need to be studied and understood for optimal sequencing. Modifying the payload to use immune-stimulating agents or combination therapies with

[Noteable]

Plenty of opportunities for ONCY.

[Noteable]

This for those fvery ew who are fixed on stock options.

[Noteable]

Should read ... those very few ..

[Noteable]

AbbVie plans to acquire ImmunoGen for $10.1 Billion, in a deal that would expand the Big Pharma’s presence in the oncology field and mark an exit for the 42-year-old Boston biotech.  ImmunoGen was founded in 1981. In early 2000 Pfizer was the first to introduce an ADC which turned into the developing plan to acquire ADC company Seagen for US$ 43 Billion. I

[Noteable]

December 10, 2023 - The strategy of combining an ADC with a PD-1 immunotherapy got a major boost recently from the combination of Seagen and Astellas’ Padcev and Merck’s Keytruda. Now Bristol Myers Squibb’s Opdivo topped Seagen’s classical Hodgkin lymphoma (cHL) therapy Adcetris in a head-to-head trial, Seagen has trotted out new datasets suggesting the two drugs—a PD-1 inhibitor and an